ReviewInternational journal of molecular sciences2021
Chronic Kidney Disease: Strategies to Retard Progression.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence and Causes of Acute Kidney Injury and Chronic Kidney Disease in Ghana: A Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2026Pooled it
- The association between steatotic liver disease and chronic kidney disease: a meta-analysis and Mendelian randomization study highlighting metabolic comorbidities.Nutrition & diabetes · 2026Pooled it
- Impact of Anemia and Comorbidity Burden on Disease Progression and Outcomes in Chronic Kidney Disease.Journal of clinical laboratory analysis · 2026Article
- [Rehmanniae radix preparata alleviates chronic kidney disease in mice through a multi-target mechanism].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Ultra-Processed Foods and Chronic Kidney Disease: Is Inflammaging the Missing Link?Biomolecules · 2026Review
- CX3CR1-T280M polymorphism and end-stage renal disease development in chronic kidney disease.Scientific reports · 2026Observational
- Prediction of Five-Year Mortality Risk of Chronic Kidney Disease Using Artificial Intelligence-Based Models: A Retrospective Study.Health science reports · 2026Article
- Five-Year Outcomes of Chronic Kidney Disease in a Longitudinal Population-Based Cohort in Western Australia.Nephrology (Carlton, Vic.) · 2026Article
- A Cross-Ethnicity Validated Machine Learning Model for the Progression of Chronic Kidney Disease in Individuals over 50 Years Old.Journal of clinical medicine · 2026Article
- Predictive Role of Hematological Biomarkers in Chronic Kidney Disease Progression.Journal of clinical laboratory analysis · 2026Article
- The impact of rising peripheral blood naïve CD8Renal failure · 2025Article
- Article
- SELENBP1 protects against kidney fibrosis in chronic kidney disease as a methanethiol oxidase.Science China. Life sciences · 2025Article
- Clinical Profile and Determinants of Chronic Kidney Disease Progression in Patients With Cardiorenal Anaemia Syndrome in Tanzania: A Descriptive Post Hoc Prospective Observational Study.Health science reports · 2025Article
- FTO inhibition attenuates renal fibrosis by downregulating ferroptosis activator ACSL4 and profibrotic factor TGFBI.iScience · 2025Article
- From Plants to Protection: Cardiorenal Benefits in Non-Diabetic Chronic Kidney Disease and Heart Failure.Molecules (Basel, Switzerland) · 2025Review
- Examining the Relationships Between Blood Cadmium, DNA Methylation Biomarker, Telomere Length, and Their Associations with Mortality in U.S. Adults.Life (Basel, Switzerland) · 2025Article
- Role of LncRNA in Pathogenesis, Diagnosis and Treatment of Chronic Kidney Disease.Cell biochemistry and biophysics · 2025Review
- Review
- Psychosocial and quality of life assessment in kidney transplant recipients: a focus on anxiety, depression, and clinical correlates.BMC nephrology · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD), defined as the presence of irreversible structural or functional kidney damages, increases the risk of poor outcomes due to its association with multiple complications, including altered mineral metabolism, anemia, metabolic acidosis, and increased cardiovascular events. The mainstay of treatments for CKD lies in the prevention of the development and progression of CKD as well as its complications. Due to the heterogeneous origins and the uncertainty in the pathogenesis of CKD, efficacious therapies for CKD remain challenging. In this review, we focus on the following four themes: first, a summary of the known factors that contribute to CKD development and progression, with an emphasis on avoiding acute kidney injury (AKI); second, an etiology-based treatment strategy for retarding CKD, including the approaches for the common and under-recognized ones; and third, the recommended approaches for ameliorating CKD complications, and the final section discusses the novel agents for counteracting CKD progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.